TirzeMax SQ was developed to treat type 2 diabetes, and it has also been shown to protect the cardiovascular system and act as a potent weight-loss agent.
6,900 UAH
Orders are processed and handed over for delivery within 1–2 business days after confirmation by a manager. We deliver throughout Ukraine with Nova Poshta to a branch, parcel locker, or by courier to your address. Delivery cost is calculated at the carrier’s rates upon receipt.
Payment: Pay on delivery · Card transfer · Bank transfer · Crypto wallet · PayPal
Mounjaro is an injectable product based on tirzepatide, developed by Eli Lilly. Originally registered for the treatment of type 2 diabetes, it is widely used by endocrinologists and general practitioners to correct excess weight. According to the SURPASS clinical trials, patients lost from 15 to 22% of body weight over 72 weeks of therapy, results beyond the reach of most other products in this group.
Mounjaro is used in two main situations:
Type 2 diabetes, to improve glycaemic control in adult patients in combination with diet and physical activity. The product lowers HbA1c by 1.8–2.4%, which surpasses most products in this group.
Correction of excess weight and obesity, in adults with a BMI ≥30 kg/m², or with a BMI ≥27 kg/m² in the presence of comorbidities (hypertension, dyslipidaemia, sleep apnoea, type 2 diabetes).
Manufactured in England
| Active ingredient | Tirzepatide |
|---|---|
| Product form | Pre-filled pen |
| Dosage | 2.5 mg |
| Volume | 2.4 ml |
| Route of administration | Subcutaneous injection |
| Requires reconstitution | No |
| Quantity per package | 4 doses |
| Country of origin | United Kingdom |